peptide technologies bpc 157 BPC-157: What It Is, What We Know, and Why Its Use for Arthritis Remains Unproven BPC-157 10mg – Research Peptide

Subcutaneous planning from a 50 mg vial reconstituted with 3.0 mL BAC water (~16.7 mg/mL) Phase Days 12 (tolerance) Daily dose 2.5 mg once daily Units on U-100 syringe 15 units Volume 0.15 mL Phase Days 3+ (standard) Daily dose 5 mg once daily Units on U-100 syringe 30 units Volume 0.30 mL Phase Split option (BID) Daily dose 2.5 mg twice daily Units on U-100 syringe 15 units each Volume 0.15 mL each Subcutaneous doses are much smaller than oral doses because of injection volume limits and because direct subQ absorption skips the gut

People with a healthy amount of B12 in their bodies tend to be less likely to experience osteoporosis later on in life

& Petryszak, P

10.1186/s12885-017-3492-1 55 DeyN.DeP.BrianL